AMPH
HEALTHCAREAmphastar P
AI Insight
What's Moving AMPH Today?
No stock-specific AI insight has been generated for AMPH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.64$31.26
$19.53
Fundamentals
Market Cap$808M
P/E Ratio11.0
EPS$1.66
Dividend Yield—
Dividend / Share—
ROE10.4%
Profit Margin11.0%
Debt / Equity—
Trading
Volume661K
Avg Volume (10D)—
Shares Outstanding44.1M
AMPH News
22 articles- New Strong Sell Stocks for June 23rdYahoo Finance·Jun 23, 2026
- 1 Healthcare Stock to Consider Right Now and 2 We Brush OffYahoo Finance·Jun 12, 2026
- Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for GrowthMarketbeat·Jun 10, 2026
- How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation ShiftsYahoo Finance·Jun 9, 2026
- Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI DragMarketbeat·Jun 4, 2026
- Amphastar (AMPH) holders approve directors, EY auditor and annual say-on-payStock Titan·Jun 3, 2026
- Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline UncertaintyYahoo Finance·Jun 2, 2026
- Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare ConferenceYahoo Finance·May 27, 2026
- 3 Stocks Under $50 with Open QuestionsYahoo Finance·May 26, 2026
- Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19Yahoo Finance·May 20, 2026
- Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower TodayYahoo Finance·May 18, 2026
- The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings CallYahoo Finance·May 17, 2026
- Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals SegmentYahoo Finance·May 16, 2026
- Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft EarningsYahoo Finance·May 15, 2026
- Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales OutlookMarketbeat·May 14, 2026
- How The Amphastar Pharmaceuticals (AMPH) Narrative Is Shifting As Targets Fall And New Drugs LaunchYahoo Finance·May 12, 2026
- Earnings Miss: Amphastar Pharmaceuticals, Inc. Missed EPS By 75% And Analysts Are Revising Their ForecastsYahoo Finance·May 11, 2026
- Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Falls Despite New Drug Launches And Licensing DealsYahoo Finance·May 9, 2026
- Amphastar Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 8, 2026
- Amphastar (AMPH) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key MetricsYahoo Finance·May 8, 2026
- Amphastar: Q1 Earnings SnapshotKING5.com·May 7, 2026
All 22 articles loaded
Price Data
Open$18.61
Previous Close$19.53
Day High$19.58
Day Low$18.50
52 Week High$31.26
52 Week Low$16.64
52-Week Range
$16.64$31.26
$19.53
Fundamentals
Market Cap$808M
P/E Ratio11.0
EPS$1.66
Dividend Yield—
Dividend / Share—
ROE10.4%
Profit Margin11.0%
Debt / Equity—
Trading
Volume661K
Avg Volume (10D)—
Shares Outstanding44.1M
About Amphastar P
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—